|
See related Vidaza powd for inj information |
|
|
|
Manufacturer |
Celgene |
|
Distributor |
Hong Kong: Jacobson Medical/Macau: Agencia Lei Va Hong |
|
Contents |
Azacitidine |
|
Indications |
Treatment of myelodysplastic syndrome subtypes: Refractory anemia or refractory anemia w/ ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia w/ excess blasts, refractory anemia w/ excess blasts in transformation & chronic myelomonocytic leukemia.
Click to view Vidaza detailed prescribing infomation |
|
Dosage |
75 mg/m2 SC or IV daily for 7 days. Cycles should be repeated every 4 wk. The dose may be increased to 100 mg/m2 if no effect is seen after 2 treatment cycles.
Click to view Vidaza detailed prescribing infomation |
|
Overdosage |
View Vidaza overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Patient w/ advanced malignant hepatic tumors.
Click to view Vidaza detailed prescribing infomation |
|
Warnings |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Vidaza detailed prescribing infomation |
|
Special Precautions |
Perform complete blood count prior to each dosing cycle. Patient w/ liver disease. Monitor patient w/ renal impairment. Pregnancy & lactation.
Click to view Vidaza detailed prescribing infomation |
|
Adverse Drug Reactions |
Nausea, anemia, thrombocytopenia, vomiting, pyrexia, leukopenia, diarrhea, fatigue, injection site erythema, constipation, neutropenia, ecchymosis.
View ADR Monitoring Form |
|
Drug Interactions |
[Click for Vidaza detailed prescribing infomation]
View more drug interactions with Vidaza |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Vidaza detailed prescribing infomation |
|
Storage |
View Vidaza storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Vidaza description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Vidaza mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
ATC Classification |
L01BC07 - azacitidine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer. |
